ATE478893T1 - Genetisch hergestellte zellen für therapeutische anwendungen - Google Patents

Genetisch hergestellte zellen für therapeutische anwendungen

Info

Publication number
ATE478893T1
ATE478893T1 AT05763600T AT05763600T ATE478893T1 AT E478893 T1 ATE478893 T1 AT E478893T1 AT 05763600 T AT05763600 T AT 05763600T AT 05763600 T AT05763600 T AT 05763600T AT E478893 T1 ATE478893 T1 AT E478893T1
Authority
AT
Austria
Prior art keywords
therapeutic applications
genetically designed
designed cells
cells
genetically
Prior art date
Application number
AT05763600T
Other languages
English (en)
Inventor
Marc Penn
Matthew Kiedrowski
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Application granted granted Critical
Publication of ATE478893T1 publication Critical patent/ATE478893T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05763600T 2004-05-19 2005-05-17 Genetisch hergestellte zellen für therapeutische anwendungen ATE478893T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57234904P 2004-05-19 2004-05-19
PCT/US2005/017050 WO2005116192A2 (en) 2004-05-19 2005-05-17 Genetically engineered cells for therapeutic applications

Publications (1)

Publication Number Publication Date
ATE478893T1 true ATE478893T1 (de) 2010-09-15

Family

ID=35451463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05763600T ATE478893T1 (de) 2004-05-19 2005-05-17 Genetisch hergestellte zellen für therapeutische anwendungen

Country Status (9)

Country Link
US (3) US20050271639A1 (de)
EP (1) EP1763538B1 (de)
JP (1) JP5095403B2 (de)
CN (1) CN101065400A (de)
AT (1) ATE478893T1 (de)
AU (1) AU2005248352B2 (de)
CA (1) CA2567177C (de)
DE (1) DE602005023158D1 (de)
WO (1) WO2005116192A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
CN101103101B (zh) * 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
GB0514300D0 (en) * 2005-07-12 2005-08-17 Fond Ct San Raffaele Imflammation
US8168169B2 (en) * 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
ES2520044T3 (es) * 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
EP2237798A2 (de) * 2007-12-12 2010-10-13 Imperial Innovations Limited Verfahren
AU2008338525B2 (en) 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
US20110165128A1 (en) * 2008-03-07 2011-07-07 Columbia University In The City Of New York Homing in mesenchymal stem cells
CA2756670A1 (en) 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
US20100247495A1 (en) * 2009-03-30 2010-09-30 Tom Ichim Treatment of Muscular Dystrophy
CA2772610C (en) 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue
CA2777783A1 (en) * 2009-10-13 2011-04-21 Allocure Inc. Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
WO2011106234A1 (en) 2010-02-25 2011-09-01 Provasculon, Inc. Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP6145089B2 (ja) 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法
EP2626369A1 (de) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Gentechnisch veränderte mesenchymale Stammzellen und ihre therapeutische Verwendung
AU2013266496B2 (en) 2012-05-21 2018-08-09 The Regents Of The University Of California Generation of human iPS cells by a synthetic self- replicative RNA
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
WO2014145199A2 (en) * 2013-03-15 2014-09-18 The Cleveland Clinic Foundation Retrograde delivery of sdf-1 for treatment of myocardial infarction
EP3068867B1 (de) 2013-11-16 2018-04-18 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
AU2014362198A1 (en) * 2013-12-13 2016-07-07 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
EP3692139B1 (de) 2017-10-03 2024-11-06 SDF BioPharma Inc. Behandlung von diabetes mit genetisch modifizierten betazellen
EP3781182A4 (de) 2018-04-18 2021-11-17 Summa Health Zusammensetzungen und verfahren zur behandlung von ischämie und kardiomyopathie
WO2020023806A1 (en) * 2018-07-25 2020-01-30 The Johns Hopkins University Compositions and methods for generation of heart field-specific progenitor cells
EP3953478A4 (de) * 2019-04-12 2022-10-26 Massachusetts Eye and Ear Infirmary Verfahren und zusammensetzungen zur verbesserung der anordnung von adeno-assoziierten viren (aavs)
CA3179969A1 (en) * 2020-04-09 2021-10-14 Wallkill BioPharma, Inc. Treating autoimmune diseases with genetically modified cells
TWI825446B (zh) * 2020-08-14 2023-12-11 中國醫藥大學 醫藥組合物治療組織缺血狀況之用途
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5602301A (en) * 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US6100242A (en) * 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US7393528B2 (en) * 1997-01-09 2008-07-01 Tvedten Stephen L Biological pesticide
US6121428A (en) * 1997-06-13 2000-09-19 Genentech, Inc. Protein recovery
WO1999003973A1 (en) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
CN1295617A (zh) * 1998-02-06 2001-05-16 科莱特诺医疗公司 血管生成因子－血管内皮细胞生长因子vegf的突变体
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
IL125532A0 (en) * 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
AU5241099A (en) * 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
WO2000059941A1 (en) * 1999-04-08 2000-10-12 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US7125856B1 (en) * 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
US6358697B2 (en) * 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
EP2324839B1 (de) * 2000-06-05 2017-08-09 The Trustees of Columbia University in the City of New York Granulozyten-kolonie-stimulierender-faktor (g-csf) zur behandlung von herzinfarkt
WO2002009650A2 (en) * 2000-07-31 2002-02-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
US20020094327A1 (en) * 2000-11-05 2002-07-18 Petersen Bryon E. Targeting pluripotent stem cells to tissues
AU2002224851A1 (en) * 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
US20020111290A1 (en) * 2000-12-01 2002-08-15 Bernhard Homey Uses of mammalian genes and related reagents
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
EP1424389A4 (de) * 2001-08-07 2004-08-25 Kirin Brewery Verfahren zur herstellung hämatopoetischer stammzellen
EP1430114B1 (de) * 2001-09-14 2012-01-18 Stem Cell Therapeutics Inc. Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US7402724B2 (en) * 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
WO2003059375A1 (en) * 2002-01-17 2003-07-24 Cardio Incorporated Complex therapy for tissue regeneration
US7396537B1 (en) * 2002-02-28 2008-07-08 The Trustees Of The University Of Pennsylvania Cell delivery patch for myocardial tissue engineering
US7282222B2 (en) * 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
JP2004099471A (ja) * 2002-09-05 2004-04-02 Cardio Corp 心筋梗塞および心不全の治療薬
WO2004044142A2 (en) * 2002-11-05 2004-05-27 The Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
US20040258670A1 (en) * 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
AU2003902037A0 (en) * 2003-04-24 2003-05-15 Mclachlan, Craig Method for tissue growth
US7396680B2 (en) * 2003-10-31 2008-07-08 Cornell Research Foundation, Inc. Stem cell-specific promoters and their use
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US20060105950A1 (en) * 2004-10-25 2006-05-18 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and use thereof to treat wounds
WO2006083394A2 (en) * 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20070173471A1 (en) * 2006-01-24 2007-07-26 Losordo Douglas W Morphogen compositions and methods of use thereof to treat heart disorders
US7405195B2 (en) * 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
ES2520044T3 (es) * 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
AU2008338525B2 (en) * 2007-12-14 2015-04-02 Juventas Therapeutics, Inc. Compositions and methods of promoting wound healing
CA2772610C (en) * 2009-08-28 2018-01-23 The Cleveland Clinic Foundation Sdf-1 delivery for treating ischemic tissue

Also Published As

Publication number Publication date
JP5095403B2 (ja) 2012-12-12
CA2567177A1 (en) 2005-12-08
EP1763538B1 (de) 2010-08-25
CN101065400A (zh) 2007-10-31
US20070258943A1 (en) 2007-11-08
DE602005023158D1 (de) 2010-10-07
WO2005116192A2 (en) 2005-12-08
AU2005248352B2 (en) 2009-07-30
CA2567177C (en) 2011-08-09
WO2005116192A3 (en) 2006-04-13
EP1763538A2 (de) 2007-03-21
US20070224171A1 (en) 2007-09-27
US20050271639A1 (en) 2005-12-08
AU2005248352A1 (en) 2005-12-08
JP2007537752A (ja) 2007-12-27

Similar Documents

Publication Publication Date Title
DE602005023158D1 (de) Genetisch hergestellte zellen für therapeutische anwendungen
ATE530638T1 (de) Pluripotente autologe stammzellen aus der mündlichen oder gastrointestinalen schleimhaut
AR069168A1 (es) Variantes de alfa -amilasas con propiedades alteradas
MY159971A (en) Multipotent/pluripotent cells and methods
EA201270187A1 (ru) Ферментативное продуцирование этанола, не содержащего глицерин
AR105435A2 (es) Método de recombinación homóloga intramolecular en el genoma de una célula vegetal
MX2015000189A (es) Celulas para producir iduronato-2-sulfatasa recombinante.
BR112012015576A2 (pt) "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso"
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
SG196784A1 (en) Stem cell cultures
MX2012007712A (es) Expresion de hexosa cinasa en celulas huesped recombinantes.
CY1107014T1 (el) Χρηση θρεπτικου μεσου κυτταροκαλλιεργειας ελευθερου ορου για την παραγωγη il-18bp σε κυτταρα θηλαστικων
MX350966B (es) Celulas madre pluripotentes.
WO2006070370A3 (en) Stem cells culture systems
EP1799812A4 (de) Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
EA201190170A1 (ru) Композиции полимера мирцена
WO2004046312A3 (en) Methods for in vitro expansion of hematopoietic stem cells
AR078346A1 (es) Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano
BR112012012192A2 (pt) b-glicosidades variantes recombinantes thermoascus aurantiacus para produção de açúcares fermentáveis a partir da biomassa celulósica
PE20130213A1 (es) Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
CA2801009C (en) Native wharton's jelly stem cells and their purification
TW200608991A (en) Chemokine combinations to mobilize progenitor/stem cells
ATE536914T1 (de) Spezifische cd4+cd25+-regulatorische t-zellen für die hämatopoetische zelltransplantation und immuntoleranz
EP2558124A4 (de) Polysaccharidzusammensetzungen und verfahren zu ihrer verwendung zur behandlung und prävention von mit vorläuferzellenmobilisierung assoziierten erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties